ANI Pharmaceuticals, Inc. announced the acceptance of its Abbreviated New Drug Application (ANDA212252) for acyclovir, a formulation intended for oral use. This approval is anticipated to expand generic competition and provide additional stability in the antiviral market once the proprietary product patent expires.